REGULATORY

LDP Finalizes Proposal for Growth Strategy; Touches on CIN, Drug Discovery Seeds

April 20, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Liberal Democratic Party’s (LDP) economic revitalization headquarters finalized a proposed plan on April 19 for the government’s new economic growth strategy. The plan includes specifics on promoting R&D in the field of healthcare, the creation of a patient registry-based…

To read the full story

LDP Proposal for New Growth Strategy to Push “Clinical Innovation Network”
April 15, 2016
Centralized Support Unit Needed for “Clinical Innovation Network”: JPMA’s Teshirogi
April 8, 2016

REGULATORY

LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…